Including those recognized to trigger Lyme Disease.

Abbott launches new molecular assay to detect vector-borne microorganisms Abbott’s Ibis Biosciences today introduced a new molecular assay to detect a wide variety of vector-borne microorganisms, including those recognized to trigger Lyme Disease, Rocky Mountain Spotted Fever, Babesiosis, Anaplasmosis and Ehrlichiosis. Vector-borne pathogens are microorganisms that are transmitted by arthropods such as ticks typically, mosquitoes or fleas. The PLEX-ID Vector-borne check is a single broad-range molecular assay that may detect a wide array of microorganisms and mixtures of microorganisms in one specimen, said Tag Eshoo, Ph.D., director, New Technology Development, Ibis Biosciences.As opposed to the triggers in the EGDT process, protocol-based standard therapy recommended packed red-cell transfusion only when the hemoglobin level was less than 7.5 g per deciliter. The protocol for standard therapy mandated administration of fluids until the team leader made the decision that the patient’s fluids had been replete. The standard-therapy protocol, just like the EGDT process, did not specify the type of vasopressor or fluid and didn’t specify nonresuscitation areas of care, which were supplied by the treating doctor.